Compare AbCellera Biologics Inc (ABCL) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Invesco S&P 500 Low Volatility ETF — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Invesco S&P 500 Low Volatility ETF trades at $76.21. Which is the better fit depends on your goals.
| ABCL | SPLV | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | — |
52-Week High | $8.12 | $77.45 |
52-Week Low | $2.78 | $70.30 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
SPLV trades at $76.17, down 0.73% today, maintaining a bullish technical outlook with strong moving average support. The ETF focuses on low-volatility S&P 500 stocks, offering defensive exposure during market uncertainty. Recent news highlights its role in portfolio diversification amid tech sector volatility, with institutional investors showing mixed positioning.
The outlook remains positive for risk-averse investors seeking stable equity exposure. Key risks include potential underperformance during strong bull markets and concentration in defensive sectors. Analyst sentiment is generally favorable for defensive portfolio allocation, though specific financial metrics for the ETF are not publicly detailed like individual stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
